United Kingdom (UK)
Recombinant monoclonal antibody to alpha 5 beta 1 Integrin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma M200 (Volociximab).
UniProt Accession Number of Target Protein: P08648
Alternative Name(s) of Target: Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e.
Immunogen: Heterodimeric α5β1Fc
fusion protein
Specificity: The antibody binds to human α5β1 integrin with a Kd of 0.367 nM (determined by Biacore), an EC50 of 0.2 nM and an IC50 of 2.3 nM.
Application Notes: The antibody binds specifically to α5β1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The α5β1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.
Antibody first published in:
Ramakrishnan et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. PMID:17024968
Note on publication:
Describes the role of α5β1 integrin in the progression of angiogenesis, and the generation of Volociximab, a chimeric monoclonal antibody whose in vitro and in vivo use is evaluated for therapeutic use.
Flow-cytometry using the anti-alpha 5 beta 1 Integrin M200 (Volociximab) (Ab00449) PBMC’s (A) and U93 cells (B) were stained with unimmunized rabbit IgG antibody (black line) or the rabbit-chimeric version of M200 (Volociximab) (Ab00449-23.0, blue line) at a concentration of 10 µg/ml for 30 mins at RT. After washing, bound antibody was detected using anti-rabbit IgG JK (FITC-conjugate) antibody (129936) at 2 µg/ml and cells analyzed on a FACSCanto flow-cytometer.
Immunofluoresence staining of fixed HeLa cells with anti-alpha 5 beta 1 Integrin antibody M200 (Volociximab) (Ab00449) Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton stained with the chimeric rabbit IgG version of M200 (Ab00449-23.0) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (1 µg/ml), showing cytoplasmic and membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab00449-23.0, DAPI, merged channels and a negative control. The negative control was stained with unimmunized rabbit IgG followed by Alexa Fluor® 488 secondary antibody.
Flow-cytometry using the anti-alpha 5 beta 1 Integrin M200 (Volociximab) (Ab00449) PBMC’s (A) and U93 cells (B) were stained with unimmunized rabbit IgG antibody (black line) or the rabbit-chimeric version of M200 (Volociximab) (Ab00449-23.0, blue line) at a concentration of 10 µg/ml for 30 mins at RT. After washing, bound antibody was detected using anti-rabbit IgG JK (FITC-conjugate) antibody (129936) at 2 µg/ml and cells analyzed on a FACSCanto flow-cytometer.